PREVYMIS® demonstrated safety profile for CMV infection and disease prophylaxis in adult CMV R+ allogeneic HSCT recipients

Prophylaxis through Week 14 (~100 days) post-HSCT: most commonly reported adverse reactions.¹

Adverse reactions reported in ≥1% of HSCT recipients in the PREVYMIS group and at a frequency greater than placebo followed through Week 24 post transplant.¹

Adverse reactions

PREVYMIS
(N=373)

Nausea

7.2%

Diarrhea

2.4%

Vomiting

1.9%

Prophylaxis from Week 14 (~100 days) through Week 28 (~200 days) post-HSCT.¹

The adverse reactions observed were consistent with those observed in the study that evaluated CMV prophylaxis through ~100 days post-HSCT.¹

References:

PREVYMIS®. Summary of product characteristics, April 2025.

Safety

PREVYMIS® demonstrated safety profile for CMV infection and disease prophylaxis in adult CMV R+ allogeneic HSCT recipients

Prophylaxis through Week 14 (~100 days) post-HSCT: most commonly reported adverse reactions.¹

Prophylaxis from Week 14 (~100 days) through Week 28 (~200 days) post-HSCT.¹

References:

Begränsat innehåll

Safety

Safety

PREVYMIS® demonstrated safety profile for CMV infection and disease prophylaxis in adult CMV R+ allogeneic HSCT recipients

Prophylaxis through Week 14 (~100 days) post-HSCT: most commonly reported adverse reactions.1

Prophylaxis from Week 14 (~100 days) through Week 28 (~200 days) post-HSCT.1

References:

Begränsat innehåll

Prophylaxis through Week 14 (~100 days) post-HSCT: most commonly reported adverse reactions.¹

Prophylaxis from Week 14 (~100 days) through Week 28 (~200 days) post-HSCT.¹